Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other

Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025

By The Northwire Desk — AI Analysis Dec 15, 2025 · 17:30 HBP · 2.05 HELIX BIOPHARMA CORP.
HBP · Price

Executive Summary

  • Helix BioPharma Corp. announced the filing of its unaudited interim financial statements for the three‑month period ended October 31, 2025, together with the accompanying MD&A and CEO/CFO certifications.
  • The filings are now publicly available on the company’s SEDAR+ profile and corporate website.
  • No additional operational or commercial updates were disclosed in this release.

Key Details

  • Interim Financial Statements: Unaudited statements for Q3 2025 (three‑month period ended 31 Oct 2025).
  • Management Discussion & Analysis (MD&A): Included with the interim filings, providing narrative context to the financial results.
  • CEO & CFO Certifications: Both executives have signed certifications confirming the accuracy of the interim statements and MD&A.
  • Access: Documents can be accessed at www.sedarplus.ca and https://www.helixbiopharma.com/filings-and-financials/.

Notable Quotes

(No executive quotes were included in the release.)

Read the original news release →

More from HELIX BIOPHARMA CORP.

Jun 12, 2026 · 18:15

Helix Biopharma Secures $3.67M Lifeline via Convertible Debentures, Cuts Losses as It Winds Down Pancreatic Trial

Earnings Mar 16, 2026 · 17:00

Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026

Earnings Feb 24, 2026 · 09:00

Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London

Other Feb 05, 2026 · 16:30

Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases

M&A / Property Oct 29, 2025 · 12:45

Helix BioPharma Corp. Announces Fiscal 2025 Year-End Results

Earnings